Peer-reviewed veterinary case report
Laser treatment plus chemo and piroxicam for dog bladder cancer
By Upton, Melinda L et al.·Published in Journal of the American Veterinary Medical Association·2006·Oncology-Internal Medicine Referral Service, United States·View original on PubMed →
PetCaseFinder translated the abstract of this peer-reviewed paper into plain English so pet owners can read it. We do not publish original research — every detail traces back to the citation above. How we work →
Original publication title: Evaluation of carbon dioxide laser ablation combined with mitoxantrone and piroxicam treatment in dogs with transitional cell carcinoma.
- Species:
- dog
Plain-English summary
Eight dogs with bladder cancer (transitional cell carcinoma) underwent a procedure using carbon dioxide laser ablation to remove tumors in the bladder and urethra. They were also treated with a chemotherapy drug called mitoxantrone and a pain reliever called piroxicam. Most dogs showed improvement, with a median survival time of about 10 months, and they quickly recovered from symptoms related to their urinary issues. While two dogs experienced mild side effects like decreased appetite and lethargy, the overall treatment was well tolerated and effective in managing the disease.
People also search for: dog bladder cancer treatment · CO2 laser for dog tumors · mitoxantrone side effects in dogs
Abstract
CASE DESCRIPTION: 8 dogs that underwent carbon dioxide (CO2) laser ablation of transitional cell carcinoma in the bladder trigone and proximal portion of the urethra and were also treated with mitotranxone and piroxicam. CLINICAL FINDINGS: Transitional cell carcinoma of the bladder frequently involves the trigone and urethra and can be difficult to manage surgically. Dogs underwent laser ablation of the primary tumor and were treated with mitoxantrone at a dosage of 5 mg/m2)every 3 weeks for 4 treatments. Piroxicam was given at a dosage of 0.3 mg/kg (0.14 mg/lb) once daily for the remaining life of the dog. TREATMENT AND OUTCOME: Median and mean disease-free intervals were 200 and 280 days, respectively. Median and mean survival times were 299 and 411 days, respectively. Adverse treatment effects were observed in 2 dogs; signs included mild, self-limiting inappetance and lethargy. The procedure appeared to be well tolerated; all treated dogs had rapid resolution of clinical signs of disease of the lower portion of the urinary tract. CLINICAL RELEVANCE: Although survival times achieved with CO2 laser ablation and treatment with mitoxantrone and piroxicam were similar to survival times associated with chemotherapy alone, resolution of clinical signs was better with the combined treatment.
Find similar cases for your pet
PetCaseFinder finds other peer-reviewed reports of pets with the same symptoms, plus a plain-English summary of what was tried across them.
Search related cases →Original publication on PubMed: https://pubmed.ncbi.nlm.nih.gov/16478428/